Clinical

Managing toxicities for patients on immunotherapy requires collaboration with specialists to manage specific organ toxicities and moving beyond steroids, according to a presentation at the ESMO Congress 2023.

Neoadjuvant cemiplimab followed by surgery resulted in favorable survival outcomes for patients with resectable stage II to IV cutaneous squamous cell carcinoma (CSCC), addressing an area of unmet need, explained Neil D. Gross, MD, FACS, of MD Anderson.

Raj Chovatiya, MD, PhD, assistant professor of dermatology at Northwestern University's Feinberg School of Medicine, discussed type 2 inflammation in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis (AD).

In a trial assessing subcutaneous OCTA101 in patients with severe hemophilia A, promising results in pharmacokinetics and efficacy were overshadowed by safety concerns.

The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis.

Patients with extensive-stage small cell lung cancer (ES-SCLC) who receive trilaciclib appear to experience lower rates of hematologic adverse effects than those who are not treated with the agent.

Geri Landman, MD, MPH, cofounder and chair of Moonshots for Unicorns, talks about how the lack of government funding for PGAP3 research led her to take it upon herself to work toward a cure for her daughter.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the impacts of immunotherapy on outcomes for certain patients with non–small cell lung cancer.

A cohort study of 65 clinical trials in multiple myeloma found that toxic effects are often described with subjective terminology that may not reflect adverse event rates reported in the studies.

Posters presented at ACAAI 2023 Annual Scientific Congress examined dupilumab use in children with moderate-to-severe asthma and in the presence of elevated type 2 biomarkers.

Researchers concluded there is a clinically important increase in infection risk among patients with T1D in both primary care and hospital settings, and that guidelines must be developed to reflect this risk and encourage earlier treatment.

This new data suggests that hospital facilities in the US may need to plan for potentially atypical timing of bronchiolitis season once more for 2023.

A key opinion leader provides insight into key HFpEF treatment strategies.

Medical experts discuss strategies to connect with patients to alleviate concerns potentially associated with converting heart failure therapies.

Researchers explained that developing preventative strategies and improving air quality to reduce the concentrations of air pollutants can help to reduce the hospitalizations of patients with chronic obstructive pulmonary disease (COPD).

Over a 52-week treatment period, the gene therapy demonstrated robust evidence for a clinically meaningful benefit, including across several prespecified functional secondary end points vs placebo.

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

Medical experts discuss interchangeability designation requirements for biosimilars.

Based on Behavioral Risk Factor Surveillance System data, about 6.4% of US adults in 2011 (14.3 million people) and about 6.5% (14.2 million) had COPD in 2021, showing that COPD prevalence did not significantly change throughout the decade.

More than 10% of fecal immunochemical test (FIT)–based colorectal cancer screening could not be processed due to unsatisfactory samples.

Chase Hendrickson, MD, MPH, Vanderbilt University Medical Center, attributes gaps in continuous glucose monitoring (CGM) prescribing rates to patient demographics, endocrinologists' longer familiarity with the technology, and the availability of ancillary support in endocrine clinics.

These new atopic dermatitis (AD) treatment guidelines from the American Academy of Dermatology (AAD) update their 2014 recommendations for the management of AD with phototherapy and systemic therapies.

Additional COVID-19 tests can be ordered amid rising cases and insurance challenges; therapies targeting toxic proteins in Alzheimer disease spark renewed interest; new poll indicates 55% approval for legal abortion on any grounds.

Amitkumar Mehta, MD, MBA, associate professor of medicine and director of the lymphoma and chimeric antigen receptor (CAR) T-cell therapy programs, University of Alabama at Birmingham, highlights the need for novel therapy approaches for patients with high-risk mantle cell lymphoma (MCL).

Stuart J Connolly, MD, FRCPC, discusses updated strategies for managing intracerebral hemorrhage, emphasizing the significance of timely diagnosis to improve hemostatic efficacy.

An artificial intelligence (AI) app can detect increased fluid in lungs by simply hearing voice changes over time—and the increased fluid in lungs can be a sign of heart failure.

Dr. Parth Rali, MD, of Temple University Hospital explained the challenges of managing patients with intermediate-risk pulmonary embolism (PE) and how risk stratification tools can help to address these challenges.

Richard Kim, MD, offers perspective regarding optimal use of health care resources in the management of HCC.

Researchers hypothesized that health care personnel (HCP) influenza vaccination coverage decreased during the pandemic because individuals may have believed that it was less important than in previous years.